ClinicalTrials.gg
CompletedNCT00466245Updated Jan 22, 2014

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

A Phase 2 interventional study of MVA Smallpox vaccine and Placebo in Smallpox, sponsored by Sanofi Pasteur, a Sanofi Company. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-22.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing MVA-BN smallpox vaccine in Smallpox — none open to participants now, none under way, none of them phase 3. MVA-BN smallpox vaccine · Smallpox.

Enrollment
4th of 16
590 · median 196
Started
2005
with 1 other
Phase 2
10 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
Sanofi Pasteur, a Sanofi Company

Among the 16 studies testing MVA-BN smallpox vaccine in Smallpox, this one is the 4th largest by enrollment, is one of 2 that started in 2005, is one of 10 in phase 2, and was the 8th registered.

Smallpox

73 studies on the registry are indexed under Smallpox; 5 are open to participants now.

Browse Smallpox studies →

Open to participants now

None of the 16 studies testing MVA-BN smallpox vaccine in Smallpox is open now. The open studies under Smallpox, anywhere →

About MVA-BN smallpox vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2 Smallpox studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing MVA-BN smallpox vaccine in Smallpox as a file.
02

Study summary

A phase 2 study to assess the MVA smallpox vaccine in previously vaccinated and vaccine- naive subjects at three dose levels.

Read the detailed description

This study will be a randomized, double-blind, placebo-controlled out-patient study conducted in multiple centers in the United States (US). Up to 700 healthy male and female adult subjects 18 to 55 years of age (inclusive), who have been previously vaccinated or subjects who are naïve to smallpox vaccine will be enrolled. Subjects will be randomized to 1 of 8 treatment groups with 100 (or 50 placebo) subjects per group in which they will receive either ACAM3000 MVA Smallpox Vaccine (1 of 3 dose levels) or placebo on Study Days 0 and 28. All personnel associated with the trial will be blinded as to treatment, with the exception of the study pharmacist who prepares the treatment for administration to each subject. There are 2 control groups in this study. A comparison of adverse events and other safety assessments between placebo and ACAM3000 MVA Smallpox Vaccine will be performed. In addition to serving as a control for safety, the previously vaccinated subjects receiving placebo will serve as a control for antibody and T-cell responses in persons with preexisting immunity who receive ACAM3000 MVA Smallpox Vaccine. Safety, tolerability, and immunogenicity data for 110 subjects undergoing primary immunization with graded doses of ACAM3000 MVA Smallpox Vaccine will be available following completion of Acambis protocol H-249-001, an ongoing phase I clinical trial. The doses levels in this study may be changed following the availability of results from protocol H-249-001. Statistical analysis will focus on comparisons among the dose levels of ACAM3000 MVA Smallpox Vaccine and comparisons of ACAM3000 MVA Smallpox Vaccine to placebo, as appropriate. A separate analysis will be performed for previously vaccinated and naïve subjects. Descriptive statistics will be used to compare demographic and baseline clinical data between stratum.

03

Conditions studied

  • Smallpox

Browse trials for

Keywords

  • MVA Vaccine
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects must be in good general health, checked on toxicity grading table.
  • for previously vaccinated subjects- must be between the ages of 33 and 55 with a previous vaccine more than 10 years ago.
  • for vaccine naive subjects- must be between the ages of 18 and 32, and have never been vaccinated for smallpox.
  • Female subjects must not be pregnant or lactating.

Exclusion criteria

Exclusion Criteria:

  • Subjects who participated in a "first responder" program.
  • any history of immunodeficiency.
  • any disease
  • any history of cardiac disease
  • any diagnosed risk factors for ischemic coronary disease
  • any history of heart palpitations or abnormalities in cardiac rhythm.
  • any current or history of eczema of any description.
  • Known allergy to MVA or any of its components, including eggs or egg products.
  • morbid obesity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
590 participants (actual)

Study arms

  • Experimental
    A

    Previously vaccinated for smallpox, 1x10-8 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    B

    Smallpox vaccine naive, 1x10-8 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    C

    Previous smallpox vaccination, 1x10-7 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    D

    Smallpox vaccine naive, 1x10-7 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    E

    Previous smallpox vaccination, 1x10-6 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    F

    Smallpox vaccine naive, 1x10-6 dose

    Drug: MVA Smallpox vaccine

  • Experimental
    G

    Previous smallpox vaccination, placebo dose

    Drug: Placebo

  • Experimental
    H

    Smallpox vaccine naive, placebo dose

    Drug: Placebo

Interventions

  • Two 0.5mL subcutaneous injections, separated by 28 days

  • DrugPlacebo

    Two 0.5mL subcutaneous injections, separated by 28 days

06

What researchers measure

Primary outcomes

  1. Safety

    Time frame: Study Completion

Secondary outcomes

  1. Immunogenicity

    Time frame: Study Completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2007
First posted
Apr 27, 2007
Start
Jul 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Jan 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00466245
Responsible party
Sponsor
First posted
Apr 27, 2007
Start date
Jul 2005
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Jan 22, 2014

Study contacts

Medical Monitor
study director · Sanofi Pasteur Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-BN smallpox vaccine

Start the discussion